Difference between revisions of "Part:BBa K1391112:Experience"

Latest revision as of 22:50, 1 November 2014

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K1391112

Cofilin is an actin binding protein that has been shown to also act as a cofactor when interacting with the receptors LilrB2 and PirB. When these receptors are activated, they recruit cofilin, which then gets activated itself. Inactive cofilin is phosphorylated at the third amino acid and it gets activated by de-phosphorylation by the receptors. The sequence for this part encodes an amino acid at the third position that is different from naturally occurring cofilin. This provides a "pseudophosphrylated" effect that we hope to limit cross reactions between other components of the cell, increasing the orthogonality of our system.

In this detection system, the receptors were fused to a linker, a TEV protease (TEVp) cleavage site and a transcription factor (in that order) at its intracellular domain. Cofilin was fused to TEV protease. These modifications allowed the manipulation of the natural operational system of receptors such that when beta-amyloid oligomers bind to the receptors (and activate them) the TEV protease on the recruited cofilin cleaves at the TEVp cleavage site. This releases the transcription factor in to the cytosol, where it is guided to the nucleus of the cell and activates some subsequent (reporter or treatment) module.

In this part, expression of cofilin can be controlled by the amount of doxycycline introduced to the cell medium via a tetracycline responsive promoter.

User Reviews

UNIQ2947222a728c48a8-partinfo-00000000-QINU UNIQ2947222a728c48a8-partinfo-00000001-QINU

@@ Line 5: / Line 5: @@
 ===Applications of BBa_K1391112===
+Cofilin is an actin binding protein that has been shown to also act as a cofactor when interacting with the receptors LilrB2 and PirB. When these receptors are activated, they recruit cofilin, which then gets activated itself. Inactive cofilin is phosphorylated at the third amino acid and it gets activated by de-phosphorylation by the receptors. The sequence for this part encodes an amino acid at the third position that is different from naturally occurring cofilin. This provides a "pseudophosphrylated" effect that we hope to limit cross reactions between other components of the cell, increasing the orthogonality of our system.
-In the brain of a patient with Alzheimer's disease, beta-amyloid protein oligomers accumulate into plaques, which are responsible for the degenerative symptoms of the disease. In order to diagnose Alzheimer's disease, this system uses beta-amyloid oligomer-specific, transmembrane receptors to detect the presence of beta-amyloid oligomers.
+In this detection system, the receptors were fused to a linker, a TEV protease (TEVp) cleavage site and a transcription factor (in that order) at its intracellular domain. Cofilin was fused to TEV protease. These modifications allowed the manipulation of the natural operational system of receptors such that when beta-amyloid oligomers bind to the receptors (and activate them) the TEV protease on the recruited cofilin cleaves at the TEVp cleavage site. This releases the transcription factor in to the cytosol, where it is guided to the nucleus of the cell and activates some subsequent (reporter or treatment) module.
-Human Leukocyte immunoglobulin-like receptor subfamily B member 2 (LilrB2) is a naturally occurring, transmembrane protein receptor that selectively binds beta-amyloid oligomers. LilrB2 belongs to a family of proteins that bind to MHC1 molecules on antigen presenting cells, and is only expressed in monocytes and B-cells (and at lower levels in dendritic cells and natural killer cells) in humans. When beta-amyloid oligomers bind to the extracellular domain of LilrB2, it becomes activated and recruits a protein called cofilin (found inside the cell) to its intracellular domain.
+In this part, expression of cofilin can be controlled by the amount of doxycycline introduced to the cell medium via a tetracycline responsive promoter.
-In this detection system, LilrB2 was fused to a linker, a TEV protease (TEVp) cleavage site and a transcription factor (in that order) at its intracellular domain. Cofilin was fused to TEV protease. These modifications allowed the manipulation of the natural operational system of LilrB2 such that when beta-amyloid oligomers bind to the receptor (and activate it) the TEV protease on the recruited cofilin cleaves at the TEVp cleavage site. This releases the transcription factor in to the cytosol, where it is guided to the nucleus of the cell and activates some subsequent (reporter or treatment) module.